Janet Sasso

Information Scientist, CAS

Bio

Janet M. Sasso earned her B.S. in Biology from The Ohio State University (OSU). She also holds her Master of Public Health from OSU where she focused her research on public health equity and education. She joined CAS in 2006 as an Information Scientist in the life sciences department curating pharmacology, pharmaceutical, environmental science, and toxicological research information. She is passionate about scientific communication to accelerate scientific analysis and inspire advancement worldwide.

新興の科学分野
With recent headlines on monkeypox, learn more about the research landscape, scientific profiles, and currently available therapies. A deeper understanding of the published science enables clarity and insight on this emerging news story.
|記事
材料
Biomaterials are making an impact on health and medicine. Experts from CAS, Ortholevo, and Westlake University discuss the full landscape.
|
創薬
薬剤リポジショニング、細胞療法、遺伝子療法を含む併用療法が、いかに希少疾患の治療改善につながっているか。
|記事
新興の科学分野
Uncover the latest advancements in understanding and treating neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Huntington’s.
|Insights Report
新興の科学分野
Experts from Lawrence Livermore National Lab, Oak Ridge National Lab, The Ohio State University, and CAS discuss major research trends in 2024.
|
新興の科学分野
CAS and Excelra delved into data surrounding biomarkers and their relationship to cancer to identify key targets for future study.
|Insights Report
バイオテクノロジー
As cancer is projected to increase, finding stronger therapeutics is more urgent. Biomarkers offer a potential solution for better diagnosis and treatment.
|記事
創薬
2018年以降、がんとの闘いにおける可能性から、抗体薬物複合体に関する研究への関心が飛躍的に増加しています。
|記事
新興の科学分野
CAS, Bayer, and Caltech explore how the gut-brain axis influences health from IBS to autism.
|
新興の科学分野
Discover the latest in anti-aging treatment strategies to promote health and longevity, including stem cell therapies, hyaluronic acid, senolytics, gene therapy, and more.
|記事
バイオテクノロジー
Exosomes have enormous potential in drug delivery, diagnostics, and more. Mayo Clinic, Direct Biologics, and Aruna Bio discuss the full landscape.
|
創薬
Landscape view of emerging contributors, companies, and researchers in the emerging field of exosome research. This article overviews key players in diagnostics and therapeutic fields of exosome research with a deeper look into the current clinical pipeline.
|記事
創薬
Expert panelists include Dr. Benjamin Ebert, the chair of Medical Oncology at the Dana-Farber Institute, Dr. Phil Chamberlain, the co-founder, President, and CEO of Neomorph, and Janet Sasso, an information scientist specializing in Life Sciences at CAS.
|
デジタル研究開発
Drug development is rapidly changing, which requires pharma companies to pivot. This is where AI drug development comes in, applying new technology to tackle an old problem.
|記事
創薬
As COVID-19 cases rise again worldwide, the Omicron subvariant BA.5 is currently the dominant strain. This blog explores some key mutations that increase transmission, evade protective antibodies, and increase the rate of (re)infection.
|記事
バイオテクノロジー
Molecular glues have been used to uncover new therapeutic agents. Because of their targeted protein degradation that holds them together, these glues have exciting potential in uncovering new drugs to fight cancer, immune diseases, and more.
|記事
バイオテクノロジー
We are in the midst of a therapeutic revolution, according to the authors of a recent review article in Frontiers in Bioengineering and Biotechnology.
|記事
バイオテクノロジー
With recent mRNA booster recommendations, many ask if they should get a COVID-19 booster and what the science shows? This blog explains the science of boosters, reviews current recommendations, and examines recent research.
|記事